Ayala Pharmaceuticals, Inc. (AYLA)

NASDAQ: AYLA · IEX Real-Time Price · USD
1.92
-0.03 (-1.56%)
May 18, 2022 12:12 PM EDT - Market open
Market Cap27.04M
Revenue (ttm)2.99M
Net Income (ttm)-40.71M
Shares Out14.09M
EPS (ttm)-2.80
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume136,972
Open2.04
Previous Close1.95
Day's Range1.86 - 2.11
52-Week Range1.86 - 14.95
Betan/a
AnalystsBuy
Price Target15.17 (+690.1%)
Earnings DateMay 13, 2022

About AYLA

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small m...

IndustryBiotechnology
IPO DateMay 8, 2020
Employees35
Stock ExchangeNASDAQ
Ticker SymbolAYLA
Full Company Profile

Financial Performance

In 2021, AYLA's revenue was $3.51 million, a decrease of -5.45% compared to the previous year's $3.71 million. Losses were -$40.25 million, 33.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for AYLA stock is "Buy." The 12-month stock price forecast is 15.17, which is an increase of 690.10% from the latest price.

Price Target
$15.17
(690.10% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 7.04% and 57.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

Ayala Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Interim data from Part A of RINGSIDE study of AL102 expected mid-2022 Interim data from Part A of RINGSIDE study of AL102 expected mid-2022

1 day ago - GlobeNewsWire

Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO)...

REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...

3 weeks ago - GlobeNewsWire

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 1.49% and 32.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...

1 month ago - Zacks Investment Research

Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

- Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 – - Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 –

1 month ago - GlobeNewsWire

Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...

2 months ago - GlobeNewsWire

Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mole...

4 months ago - GlobeNewsWire

How Much Upside is Left in Ayala Pharmaceuticals, Inc. (AYLA)? Wall Street Analysts Think 116%

The average of price targets set by Wall Street analysts indicates a potential upside of 115.8% in Ayala Pharmaceuticals, Inc. (AYLA). While the effectiveness of this highly sought-after metric is quest...

6 months ago - Zacks Investment Research

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Misses Revenue Estimates

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 10.53% and -23.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...

6 months ago - Zacks Investment Research

Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

- Presented Preliminary Clinical Data from 6mg Cohort of Phase 2 ACCURACY Trial of AL101 in R/M ACC Demonstrating 70% Disease Control Rate at ESMO 2021 –

6 months ago - GlobeNewsWire

Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference

REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mole...

6 months ago - GlobeNewsWire

Earnings Preview: Ayala Pharmaceuticals, Inc. (AYLA) Q3 Earnings Expected to Decline

Ayala Pharmaceuticals, Inc. (AYLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101

Ayala Pharmaceuticals Inc (NASDAQ: AYLA) announced new preliminary data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) ha...

8 months ago - Benzinga

Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...

8 months ago - GlobeNewsWire

Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from C...

REHOVOT, Israel and WILMINGTON, Del., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...

8 months ago - GlobeNewsWire

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Lags Revenue Estimates

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -19.05% and -25.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st...

9 months ago - Zacks Investment Research

Recap: Ayala Pharmaceuticals Q2 Earnings

Shares of Ayala Pharmaceuticals (NASDAQ:AYLA) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were down 1.35% over the past year to ($0.75), which missed the e...

9 months ago - Benzinga

Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

- Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors

9 months ago - GlobeNewsWire

Will Ayala Pharmaceuticals, Inc. (AYLA) Report Negative Q2 Earnings? What You Should Know

Ayala Pharmaceuticals, Inc. (AYLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

REHOVOT, Israel & WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecu...

10 months ago - GlobeNewsWire

Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

- First Patient Dosed in Phase 1 AL102 Combination Trial with Novartis' Anti-BCMA Agent for the Treatment of Multiple Myeloma -

1 year ago - GlobeNewsWire

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targe...

REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...

1 year ago - GlobeNewsWire

Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update

- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023

1 year ago - GlobeNewsWire

Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors

Ayala Pharmaceuticals Inc (NASDAQ: AYLA) will raise $25 million via a private placement of around 1.7 million units at $15 per unit from institutional investors, including Redmile Group and SIO Capital ...

1 year ago - Benzinga

Ayala Pharmaceuticals Announces $25 Million Strategic Financing

Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023

1 year ago - GlobeNewsWire